Orfan Biotech was founded in 2017 with the aim of developing new therapies for diseases of hyperoxaluria.
Based on the initial discoveries of its scientific founder, Dr. Eduardo Salido at the University of La Laguna in the Canary Islands, Orfan Biotech has quickly developed new compounds for the treatment of primary hyperoxaluria and related conditions. Currently the focus of the company is the genetic, and rare, disease primary hyperoxaluria (PH1). A disease for which the only cure is a double kidney and liver transplant.
Orfan Biotech, an affiliate of BridgeBio Pharma, is led by veteran biotechnology executives whose objective is to partner with patients and physicians to develop a safe and effective treatment for hyperoxalurias as quickly as possible.